We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B Turnover 41.06%
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.3B
AUM Growth
-$263M
Cap. Flow
-$30.3M
Cap. Flow %
-2.33%
Top 10 Hldgs %
46.95%
Holding
119
New
12
Increased
27
Reduced
37
Closed
33
Avg Time Held Equity + Options
0.9 years
Top 10 Avg Time Held Equity + Options
0.8 years
Top 20 Avg Time Held Equity + Options
1 year
Avg Time Held Equity only
1 year
Top 10 Avg Time Held Equity only
0.7 years
Top 20 Avg Time Held Equity only
1.1 years

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$41.1M
2
MASI icon
Masimo
MASI
+$40.1M
3
GSK icon
GSK
GSK
+$30.1M
4
HCA icon
HCA Healthcare
HCA
+$15.7M
5
RCM icon
R1 RCM Inc. Common Stock
RCM
+$15.4M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$22.8M
2
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$21.8M
3
UTHR icon
United Therapeutics
UTHR
+$19M
4
NVST icon
Envista
NVST
+$12.9M
5
HUM icon
Humana
HUM
+$12.7M

Sector Composition

Rank Sector Weight
1 Healthcare 78.97%
2 Miscellaneous 18.23%
3 Industrials 2.8%
4 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ADAP
76
DELISTED
Adaptimmune Therapeutics
ADAP
$488K 0.04%
237,086
-111,630
-32% -$301K
2021 Q3
2 quarters
SRGA
77
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
$479K 0.04%
52,460
-11,498
-18% -$175K
2021 Q1
4 quarters
TECH icon
78
Bio-Techne
TECH
$11.4B
$460K 0.04%
+4,248
New +$438K
2022 Q1
0 quarters
ELDN icon
79
Eledon Pharmaceuticals
ELDN
$173M
$449K 0.03%
114,008
– –
2021 Q3
2 quarters
IWO icon
80
PUT
iShares Russell 2000 Growth ETF
IWO
$13.4B
$435K 0.03%
1,700
-88,300
-98% -$22.6M
2021 Q4
1 quarter
MREO icon
81
Mereo BioPharma
MREO
$48.4M
$415K 0.03%
370,170
+110,700
+43% +$143K
2021 Q3
2 quarters
KRSA
82
Korsana Biosciences, Inc. Common Stock
KRSA
$1.47B
$413K 0.03%
2,657
– –
2021 Q3
2 quarters
TECX icon
83
Tectonic Therapeutic
TECX
$404M
$390K 0.03%
24,614
-802
-3% -$16.6K
2021 Q3
2 quarters
ORTX
84
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$299K 0.02%
41,958
– –
2021 Q3
2 quarters
CBIO icon
85
Crescent Biopharma
CBIO
$440M
$115K 0.01%
1,006
+6
+0.6% +$704
2021 Q4
1 quarter
CLVS
86
DELISTED
Clovis Oncology, Inc.
CLVS
$60.6K ﹤0.01%
+30,000
New +$58.9K
2022 Q1
0 quarters
ACAD icon
87
CALL
Acadia Pharmaceuticals
ACAD
$3.29B
– –
-84,600
Closed -$1.97M –
ARKG icon
88
CALL
ARK Genomic Revolution ETF
ARKG
$1.98B
– –
-243,800
Closed -$14.9M –
ARKK icon
89
ARK Innovation ETF
ARKK
$8.5B
– –
-119,118
Closed -$11.3M –
AUPH icon
90
Aurinia Pharmaceuticals
AUPH
$2.2B
– –
-201,384
Closed -$4.61M –
BKD icon
91
Brookdale Senior Living
BKD
$2.41B
– –
-79,146
Closed -$408K –
CVAC icon
92
DELISTED
CureVac
CVAC
– –
-85,017
Closed -$2.92M –
CYH icon
93
CALL
Community Health Systems
CYH
$406M
– –
-1,277,200
Closed -$17M –
ESTA icon
94
Establishment Labs
ESTA
$1.76B
– –
-25,137
Closed -$1.7M –
HUM icon
95
Humana
HUM
$49.6B
– –
-27,382
Closed -$12.7M –
IWM icon
96
PUT
iShares Russell 2000 ETF
IWM
$76.2B
– –
-125,000
Closed -$27.8M –
JYNT icon
97
PUT
The Joint Corp
JYNT
$99.4M
– –
-5,500
Closed -$361K –
LXRX icon
98
Lexicon Pharmaceuticals
LXRX
$676M
– –
-797,694
Closed -$3.14M –
MNKD icon
99
CALL
MannKind Corp
MNKD
$977M
– –
-50,000
Closed -$219K –
MRVI icon
100
Maravai LifeSciences
MRVI
$1.01B
– –
-87,795
Closed -$3.68M –
1 2 3
4
5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return
FWP
FAS Wealth Partners Leawood, Kansas $1.92B AUM 26.86% 1-Year Est. Return

Eversept Partners's Q1 2022 Portfolio in Review

As of Q1 2022, Eversept Partners held 119 positions worth $1.3B, down 17% from $1.57B the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Eversept Partners's Q1 2022 filing shows 12 new, 27 increased, 37 reduced and 33 closed positions. Its largest new stake was Masimo: 208,970 shares worth $30.4M. The largest sale was McKesson, an estimated $22.8M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, up from 72% a quarter earlier, followed by Miscellaneous and Industrials.

  • Eversept Partners's largest Q1 2022 buy was Masimo: 208,970 shares worth $30.4M.
  • Eversept Partners added most to Biohaven Pharmaceutical Holding Company Ltd. in Q1 2022, an estimated $41.1M increase.
  • Eversept Partners's biggest Q1 2022 reduction was McKesson, cutting an estimated $22.8M.
  • Eversept Partners fully exited Humana in Q1 2022, selling an estimated $12.7M.
  • Eversept Partners's ten largest holdings make up 47% of its $1.3B portfolio in Q1 2022.
  • Eversept Partners opened 12 new positions and closed 33 in Q1 2022.
  • Eversept Partners's portfolio value fell 17% quarter-over-quarter to $1.3B.

Based on Eversept Partners's 13F filing for Q1 2022, filed 16 May 2022.